文献速递头颈部肿瘤放疗

复发或第二原发头颈癌再程放疗:SBRT与IMRT多中心比较

A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-04-24

这项多中心回顾性分析比较了IMRT与SBRT用于不可切除复发或第二原发头颈鳞癌再程放疗的效果。未调整的2年OS率IMRT为35.4%、SBRT为16.3%(P<.01),但经治疗逆概率加权Cox回归后两者OS和局部区域失败无显著差异。RPA II类患者中IMRT与OS改善相关,SBRT≥35 Gy照射小肿瘤体积时OS可比。

要点

  • 未调整2年OS率IMRT 35.4%高于SBRT 16.3%,但加权后无显著差异
  • RPA II类患者中IMRT与OS改善相关(P<.001)
  • SBRT≥35 Gy照射小肿瘤体积时OS与IMRT可比

核心结论

  • 再程放疗SBRT与IMRT均相对安全,毒性优于历史研究。
  • 经治疗逆概率加权后IMRT与SBRT的OS和局部区域失败无显著差异。
  • RPA II类患者中IMRT与OS改善相关(P<.001)。
  • RPA III类患者生存差,需要替代策略。

研究设计与样本

  • 多中心回顾性分析,纳入8家机构不可切除rSCCHN且既往照射≥40 Gy接受IMRT或SBRT再程放疗的患者。
  • 共414例:IMRT 217例,SBRT 197例。
  • 采用治疗逆概率加权Cox回归和按RPA分类的子集分析控制基线差异。

主要发现

  • 未调整2年OS率IMRT为35.4%,SBRT为16.3%(P<.01)。
  • SBRT患者中RPA分类与OS保持独立关联。
  • 按RPA分类分析:III类患者IMRT与SBRT的OS相似;II类患者中IMRT与OS改善相关(P<.001)。
  • SBRT≥35 Gy照射小肿瘤体积时OS与IMRT可比。
  • 急性≥4级毒性IMRT组高于SBRT组(5.1% vs 0.5%,P<.01),晚期毒性无显著差异。

关键数值与推荐

  • 既往照射剂量≥40 Gy。
  • RPA分类:II类为不可切除肿瘤且治疗间隔>2年,或≤2年但无喂养管或气管造口依赖;III类为其他不可切除肿瘤患者。
  • SBRT照射小肿瘤体积时剂量≥35 Gy与IMRT的OS可比。

临床怎么用

  • 再程放疗可选择SBRT或IMRT,两者相对安全且毒性优于历史研究。
  • 按RPA分类评估预后并指导治疗选择:II类患者IMRT与OS改善相关。
  • SBRT治疗小肿瘤体积时给予≥35 Gy可获得与IMRT可比的OS。
  • III类患者生存差,应考虑替代策略并用于临床试验设计。

局限性

  • 回顾性多中心分析,存在基线差异,需治疗逆概率加权和子集分析控制。
  • 原文未报告随访时间、具体剂量分布及多变量模型细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Two modern methods of reirradiation, intensity modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT), are established for patients with recurrent or second primary squamous cell carcinoma of the head and neck (rSCCHN). We performed a retrospective multi-institutional analysis to compare methods. METHODS AND MATERIALS: Data from patients with unresectable rSCCHN previously irradiated to ≥40 Gy who underwent reirradiation with IMRT or SBRT were collected from 8 institutions. First, the prognostic value of our IMRT-based recursive partitioning analysis (RPA) separating those patients with unresectable tumors with an intertreatment interval >2 years or those with ≤2 years and without feeding tube or tracheostomy dependence (class II) from other patients with unresected tumors (class III) was investigated among SBRT patients. Overall survival (OS) and locoregional failure were then compared between IMRT and SBRT by use of 2 methods to control for baseline differences: Cox regression weighted by the inverse probability of treatment and subset analysis by RPA classification. RESULTS: The study included 414 patients with unresectable rSCCHN: 217 with IMRT and 197 with SBRT. The unadjusted 2-year OS rate was 35.4% for IMRT and 16.3% for SBRT (P<.01). Among SBRT patients, RPA classification retained an independent association with OS. On Cox regression weighted by the inverse probability of treatment, no significant differences in OS or locoregional failure between IMRT and SBRT were demonstrated. Analysis by RPA class showed similar OS between IMRT and SBRT for class III patients. In all class II patients, IMRT was associated with improved OS (P<.001). Further subset analysis demonstrated comparable OS when ≥35 Gy was delivered with SBRT to small tumor volumes. Acute grade ≥4 toxicity was greater in the IMRT group than in the SBRT group (5.1% vs 0.5%, P<.01), with no significant difference in late toxicity. CONCLUSIONS: Reirradiation both with SBRT and with IMRT appear relatively safe with favorable toxicity compared with historical studies. Outcomes vary by RPA class, which informs clinical trial design. Survival is poor in class III patients, and alternative strategies are needed.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Vargo JA, Ward MC, Caudell JJ, et al. A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 28899556. doi:10.1016/j.ijrobp.2017.04.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。